$TWST

Leproust Emily M. sold $2.5M of TWST

Leproust Emily M. (Chief Executive Officer) sold 19,952 shares of Twist Bioscience Corp (TWST) at $125.08 ($2.50M total) on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Aug 14, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the record of insider selling activity, but the text provides no new company performance, guidance, or regulatory developments.

02

Market read

Traders may note the insider sale size and timing, but there is no fundamental catalyst in the filing excerpt.

03

What to watch

The article does not state whether the CEO’s remaining holdings changed materially versus prior plans, nor does it provide context on total planned sales.

Relevance 5/10Novelty 3/10Timing: filed Aug 14, transaction dated Aug 12

Background

This is an SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Twist Bioscience CEO Leproust sold 19,952 shares in an open-market transaction for about $2.50M under a 10b5-1 plan.

Expected impact

Likely limited immediate impact; any reaction should be small and short-lived unless accompanied by other news.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 open-market sale with no accompanying operational or financial guidance changes in the text.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 can be purely mechanical and may not signal reduced confidence.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale by its CEO.

  • Emily M. Leproust

    CEO and officer/director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.